Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C S Higano
Phase III, Randomized, Placebo-Controlled Study of Once-Daily Oral Zibotentan (ZD4054) in Patients With Non-Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer and Prostatic Diseases
Cancer Research
Oncology
Urology
Related publications
Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The Lancet Oncology
Oncology
Corrections To: Once-Daily Controlled-Release Pregabalin in the Treatment of Patients With Fibromyalgia: A Phase III, Double-Blind, Randomized Withdrawal, Placebo-Controlled Study
Current Medical Research and Opinion
Medicine
Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research
Cancer Research
Oncology
Phase 1 Trial of High-Dose Exogenous Testosterone in Patients With Castration-Resistant Metastatic Prostate Cancer
European Urology
Urology
Exploratory Analysis of the Visceral Disease Subgroup in a Phase III Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer and Prostatic Diseases
Cancer Research
Oncology
Urology
PCN120 Quality of Life Among German Patients With Metastatic Castration-Resistant Prostate Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Lipegfilgrastim in Patients With Non-Small Cell Lung Cancer Receiving Myelosuppressive Therapy
SpringerPlus
Multidisciplinary
Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer
Urologic Oncology: Seminars and Original Investigations
Oncology
Urology
Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial
The Lancet Oncology
Oncology
